Logo image of ENTO

ENTERO THERAPEUTICS INC (ENTO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ENTO - US33749P5070 - Common Stock

2.99 USD
+0.15 (+5.28%)
Last: 11/28/2025, 8:25:57 PM
3.2 USD
+0.21 (+7.02%)
After Hours: 11/28/2025, 8:25:57 PM
Fundamental Rating

1

Overall ENTO gets a fundamental rating of 1 out of 10. We evaluated ENTO against 530 industry peers in the Biotechnology industry. ENTO has a bad profitability rating. Also its financial health evaluation is rather negative. ENTO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTO had negative earnings in the past year.
In the past year ENTO has reported a negative cash flow from operations.
In the past 5 years ENTO always reported negative net income.
In the past 5 years ENTO always reported negative operating cash flow.
ENTO Yearly Net Income VS EBIT VS OCF VS FCFENTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -20.48%, ENTO is doing good in the industry, outperforming 75.33% of the companies in the same industry.
ENTO has a better Return On Equity (-31.45%) than 75.33% of its industry peers.
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENTO Yearly ROA, ROE, ROICENTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

ENTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTO Yearly Profit, Operating, Gross MarginsENTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ENTO has been increased compared to 1 year ago.
ENTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTO Yearly Shares OutstandingENTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
ENTO Yearly Total Debt VS Total AssetsENTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ENTO has an Altman-Z score of -2.59. This is a bad value and indicates that ENTO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ENTO (-2.59) is comparable to the rest of the industry.
ENTO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, ENTO is in line with its industry, outperforming 43.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -2.59
ROIC/WACCN/A
WACCN/A
ENTO Yearly LT Debt VS Equity VS FCFENTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.81 indicates that ENTO has no problem at all paying its short term obligations.
ENTO has a Current ratio of 2.81. This is in the lower half of the industry: ENTO underperforms 67.66% of its industry peers.
ENTO has a Quick Ratio of 2.81. This indicates that ENTO is financially healthy and has no problem in meeting its short term obligations.
ENTO's Quick ratio of 2.81 is on the low side compared to the rest of the industry. ENTO is outperformed by 65.79% of its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.81
ENTO Yearly Current Assets VS Current LiabilitesENTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.71% over the past year.
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ENTO will show a very strong growth in Earnings Per Share. The EPS will grow by 31.66% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTO Yearly Revenue VS EstimatesENTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 100M 200M 300M
ENTO Yearly EPS VS EstimatesENTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100K -200K -300K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ENTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTO Price Earnings VS Forward Price EarningsENTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTO Per share dataENTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

ENTO's earnings are expected to decrease with -13.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENTO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTERO THERAPEUTICS INC

NASDAQ:ENTO (11/28/2025, 8:25:57 PM)

After market: 3.2 +0.21 (+7.02%)

2.99

+0.15 (+5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2025-11-11
Earnings (Next)03-30 2026-03-30/amc
Inst Owners4.54%
Inst Owner Change0%
Ins Owners2.89%
Ins Owner Change0%
Market Cap10.05M
Revenue(TTM)N/A
Net Income(TTM)-17.42M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-11.09
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0
BVpS16.48
TBVpS15.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.48%
ROE -31.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.81
Altman-Z -2.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.12%
EPS Next Y-34.51%
EPS Next 2Y-24.09%
EPS Next 3Y-13.45%
EPS Next 5Y31.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.53%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERO THERAPEUTICS INC / ENTO FAQ

What is the fundamental rating for ENTO stock?

ChartMill assigns a fundamental rating of 1 / 10 to ENTO.


What is the valuation status of ENTERO THERAPEUTICS INC (ENTO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTERO THERAPEUTICS INC (ENTO). This can be considered as Overvalued.


What is the profitability of ENTO stock?

ENTERO THERAPEUTICS INC (ENTO) has a profitability rating of 1 / 10.


What is the financial health of ENTERO THERAPEUTICS INC (ENTO) stock?

The financial health rating of ENTERO THERAPEUTICS INC (ENTO) is 3 / 10.


Can you provide the expected EPS growth for ENTO stock?

The Earnings per Share (EPS) of ENTERO THERAPEUTICS INC (ENTO) is expected to decline by -34.51% in the next year.